1Liu X, Marmorstein R. Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev,2007,21 : 2711-2716.
2Zhou RR, Jia SF, Zhou Z, et al. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther,2002 ,9 :407-413.
3Itamochi H, Kigawa I, Kanamori Y, et al. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma:a potential treatment strategy. Mol Cancer Ther,2007 ,6 :227-235.
4Bartholomeusz C, Itamochi H, Nitta M, et al. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene,2006 ,25 :79-90.
5Sanchez PR, Lieonart M, Cajal SR. Lack of correlation between p53 protein level and sensitivity of DNA-damaging agents in keratinocytes carrying adenovirus E1A mutants. Oncogene, 2005,11 : 675-682.
6Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the eytotoxieity of anticancer agents. Cell, 2003,74 : 957 -967.
7Chougule PB, Akhtar MS, Akerley W, et al. Chemoradiotherapy for advanced inoperable head and neck cancer: a phase Ⅱ study. Semin Radiat Oncol ,2004,9:58-63.
